AUS
NZ
UK
CA
USA
IND
Highlights
- Prescient opens its first US trial site for PTX-100
- Clinical trial expansion targets cutaneous T-cell lymphoma
- Innovative GGT-1 blocker aims to meet urgent medical needs
Prescient Therapeutics (ASX:PTX) has confirmed the initiation of its first US clinical site at the Massey Comprehensive Cancer Centre for its Phase 2a study of PTX-100, a therapy designed for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). This development adds to the company’s existing trial sites in Australia and marks a key milestone in its global trial expansion. Although not part of the ASX 200, the biotech's clinical advancements have started drawing increased attention within the healthcare investment space.
The Phase 2a study is set to evaluate the dosage of PTX-100 in around 40 patients, while a subsequent Phase 2b will focus on efficacy and safety across 75 patients. With multiple clinical endpoints including progression-free survival, response rates, and quality of life, the trial aims to explore how this first-in-class therapy can address significant unmet needs in the oncology field.
PTX-100 stands out as the only known GGT-1 inhibitor in clinical development globally. It works by disrupting key signaling pathways (Rho, Rac, and Ral) in cancer cells, which are essential for tumor survival and progression. Administered intravenously, the therapy has already shown potential benefits in early studies, particularly in patients who previously experienced relapse after standard treatments.
This investigational drug has its roots in academic research and was developed to target Ras-dependent cancers, a pathway known for its involvement in aggressive tumor behavior. Earlier trials demonstrated stable disease outcomes in a number of participants and a promising safety profile, laying the groundwork for further exploration in advanced studies.
To support its ongoing clinical programs, Prescient has extended its share purchase plan (SPP) deadline, providing additional opportunity for eligible stakeholders to participate. The funding is expected to bolster PTX-100 development and prepare the company for future regulatory milestones, which could eventually lead to broader patient access.
As the US site comes online and more patients begin enrollment, Prescient Therapeutics (PTX) moves one step closer to transforming the treatment landscape for a complex and often overlooked cancer. The therapy’s potential to act alone or in combination with other treatments opens up promising possibilities in oncology care going forward.
